Dr. Beeram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4383 Medical Dr
Fl 3
San Antonio, TX 78229Phone+1 210-593-5700Fax+1 210-617-7021
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
- SUNY Downstate Health Sciences University/Long Island College HospitalResidency, Internal Medicine, 1997 - 2000
- Osmania Medical College NTR UHSClass of 1994
Certifications & Licensure
- TX State Medical License 2005 - 2025
Clinical Trials
- Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 May 01
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2005 Sep 01
- Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2012 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsImlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10 - 55 citationsZanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and...Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, Do-Youn Oh, Diana L Hanna
The Lancet. Oncology. 2022-12-01 - 11 citationsSafety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn, Amy Mirabella
Cancer Chemotherapy and Pharmacology. 2021-11-08
Press Mentions
- Combinations with Abemaciclib Show Long-Term Disease Control in Advanced Breast CancerOctober 19th, 2016
Professional Memberships
- Member
- American Association for Cancer ResearchMember
Other Languages
- Spanish, Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: